Rapport Therapeutics Inc (NASDAQ:RAPP)’s traded shares stood at 0.46 million during the last session. At the close of trading, the stock’s price was $10.03, to imply a decrease of -6.61% or -$0.71 in intraday trading. The RAPP share’s 52-week high remains $29.74, putting it -196.51% down since that peak but still an impressive -4.89% since price per share fell to its 52-week low of $10.52.
Analysts have given a consensus recommendation of Buy for Rapport Therapeutics Inc (RAPP), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give RAPP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.7.
Rapport Therapeutics Inc (NASDAQ:RAPP) trade information
After registering a -6.61% downside in the last session, Rapport Therapeutics Inc (RAPP) has traded red over the past five days. The 5-day price performance for the stock is -20.90%, and -35.83% over 30 days. With these gigs, the year-to-date price performance is -43.46%.
The extremes give us $35 and $35 for target low and target high price respectively. As such, RAPP has been trading -248.95% off suggested target high and -248.95% from its likely low.
RAPP Dividends
Rapport Therapeutics Inc has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have Fidelity Growth Company Fund and Smallcap World Fund as the top two Mutual Funds with the largest holdings of the Rapport Therapeutics Inc (RAPP) shares. Going by data provided on Dec 31, 2024 , Fidelity Growth Company Fund holds roughly 1.53 shares. This is just over 4.17% of the total shares, with a market valuation of $15.3 million. Data from the same date shows that the other fund manager holds a little less at 861.61, or 2.36% of the shares, all valued at about 8.64 million.
